Epigenetic-targeted nanomedicine in cancer: from molecular mechanisms to therapeutic revolution
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Tumour heterogeneity and metastasis at single-cell resolution10.1038/s41556-018-0236-7 ↗
2. Hallmarks of Cancer: New Dimensions10.1158/2159-8290.CD-21-1059 ↗
3. The Hallmarks of Cancer as Eco-Evolutionary Processes10.1158/2159-8290.CD-24-0861 ↗
4. Guo · Epigenetic heterogeneity in cancer. Biomark Res. · 2019 · 7 · 23
5. Hallmarks of cancer-Then and now, and beyond10.1016/j.cell.2025.12.049 ↗
6. Cancer, metastasis, and the epigenome10.1186/s12943-024-02069-w ↗
7. Novel epigenetic therapeutic strategies and targets in cancer10.1016/j.bbadis.2022.166552 ↗
8. Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities10.1002/cac2.12374 ↗
9. Epigenetics: a landscape takes shape10.1016/j.cell.2007.02.006 ↗
10. Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications10.1038/s41392-025-02334-4 ↗
11. Epigenetics in alternative pre-mRNA splicing10.1016/j.cell.2010.11.056 ↗
12. Targeting the epigenetic regulation of antitumour immunity10.1038/s41573-020-0077-5 ↗
13. Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications10.1016/j.ccell.2025.12.001 ↗
14. Epigenetics of colorectal cancer: biomarker and therapeutic potential10.1038/s41575-019-0230-y ↗
15. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer10.1186/s12943-020-01170-0 ↗
16. Epigenetic remodeling under oxidative stress: Mechanisms driving tumor metastasis
17. Turning Cold into Hot: Firing up the Tumor Microenvironment10.1016/j.trecan.2020.02.022 ↗
18. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance10.1146/annurev-pathol-042020-042741 ↗
19. Epigenetic Therapies for Cancer10.1056/NEJMra1805035 ↗
20. Towards a more precise therapy in cancer: Exploring epigenetic complexity10.1016/j.cbpa.2020.04.008 ↗
21. Genetic and epigenetic defects of the RNA modification machinery in cancer10.1016/j.tig.2022.10.004 ↗
22. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends10.1186/s12929-021-00721-x ↗
23. Lu P, Chan YT, Kwok CF, Li Q, Jiang Z, Xu L, et al. Histone modifications across cancers: mechanisms, therapy and clinical translation. Mol Cancer. 2026. Epub ahead of print. Doi: 10.1186/s12943-026-02707-5.10.1186/s12943-026-02707-5 ↗
24. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy10.1016/j.lfs.2021.119504 ↗
25. Epigenetic basis and targeting of cancer metastasis10.1016/j.trecan.2021.11.008 ↗
26. The timeline of epigenetic drug discovery: from reality to dreams10.1186/s13148-019-0776-0 ↗
27. Epigenetic Alterations in Pancreatic Cancer Metastasis10.3390/biom11081082 ↗
28. Cancer epigenetics: from mechanism to therapy10.1016/j.cell.2012.06.013 ↗
29. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise10.1038/s41571-019-0267-4 ↗
30. Cancer epigenetics in clinical practice
31. Epigenetics-targeted drugs: current paradigms and future challenges10.1038/s41392-024-02039-0 ↗
32. PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance10.2174/1568009621666210203110857 ↗
33. Bourgeois · Epigenetic Therapies. Csh Perspect Med. · 2026 · 16
34. Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer10.1186/s12951-022-01626-z ↗
35. Nano drug delivery systems for advanced immune checkpoint blockade therapy10.7150/thno.112475 ↗
36. Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective10.1016/j.ebiom.2024.105301 ↗
37. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer10.1039/C8CS00618K ↗
38. Advances and applications of nanoparticles in cancer therapy10.1002/mog2.67 ↗
39. Epigenetic reprogramming during prostate cancer progression: A perspective from development10.1016/j.semcancer.2021.01.009 ↗
40. Nanomedicine Reimagined: Translational Strategies for Precision Tumor Theranostics
41. Stimuli-Responsive Supramolecular Biomaterials for Cancer Theranostics
42. Nanomedicine to overcome cancer multidrug resistance10.2174/1389200215666140926154443 ↗
43. Biomarker-driven molecular imaging probes in radiotherapy10.7150/thno.97768 ↗
44. Epigenetic regulation of cancer stemness10.1038/s41392-025-02340-6 ↗
45. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance10.1038/s41392-025-02266-z ↗
46. The Epigenetic Hallmarks of Cancer10.1158/2159-8290.CD-24-0296 ↗
47. Metabolic reprogramming and epigenetic modifications on the path to cancer10.1007/s13238-021-00846-7 ↗
48. A decade of exploring the cancer epigenome - biological and translational implications10.1038/nrc3130 ↗
49. TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway10.3802/jgo.2024.35.e64 ↗
50. Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications10.1016/j.semcancer.2020.08.009 ↗
51. Navigating the DNA methylation landscape of cancer10.1016/j.tig.2021.05.002 ↗
52. DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis10.1146/annurev-pathol-042220-022304 ↗
53. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation10.1038/nrg.2017.80 ↗
54. Role of TET enzymes in DNA methylation, development, and cancer10.1101/gad.276568.115 ↗
55. DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats10.1038/ng.3889 ↗
56. Targeting Epigenetics in Cancer10.1146/annurev-pharmtox-010716-105106 ↗
57. Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer10.1186/s40164-026-00760-w ↗
58. Epigenetic modifications of histones in cancer10.1186/s13059-019-1870-5 ↗
59. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment10.1038/s41423-020-0505-9 ↗
60. Epigenetics in hepatocellular carcinoma10.1016/j.semcancer.2021.07.017 ↗
61. Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases10.1038/s41392-024-01918-w ↗
62. The histone-modified landscape: Core mechanisms of osimertinib resistance in EGFR-mutant lung cancer10.1016/j.canlet.2026.218321 ↗
63. Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress10.1016/j.semcancer.2020.07.015 ↗
64. Histone acetyltransferases as promising therapeutic targets in glioblastoma resistance10.1016/j.canlet.2024.217269 ↗
65. Epigenetic regulation during cancer transitions across 11 tumour types10.1038/s41586-023-06682-5 ↗
66. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy
67. Role of RNA modifications in cancer10.1038/s41568-020-0253-2 ↗
68. Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine10.1038/s41392-022-01003-0 ↗
69. The role of m6A RNA methylation in cancer10.1016/j.biopha.2019.108613 ↗
70. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control10.1038/nature24678 ↗
71. The role and mechanism of METTL3 in cancer: emerging insights into m6A methylation and therapeutic potential10.1186/s40001-025-03351-3 ↗
72. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase10.1016/j.ccell.2016.11.017 ↗
73. Non-coding RNAs in disease: from mechanisms to therapeutics10.1038/s41576-023-00662-1 ↗
74. CircRNA and lncRNA-encoded peptide in diseases, an update review10.1186/s12943-024-02131-7 ↗
75. MicroRNA in cancer therapy: breakthroughs and challenges in early clinical applications10.1186/s13046-025-03391-x ↗
76. Effects of miR-21 on proliferation and apoptosis of WT cells via PTEN/Akt pathway
77. miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review10.1016/j.omtn.2022.02.005 ↗
78. LncRNA-encoded peptides in cancer10.1186/s13045-024-01591-0 ↗
79. Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling10.1186/s12943-022-01578-w ↗
80. An oncopeptide regulates m(6)A recognition by the m(6)A reader IGF2BP1 and tumorigenesis10.1038/s41467-020-15403-9 ↗
81. The emerging roles of circRNAs in cancer and oncology10.1038/s41571-021-00585-y ↗
82. CircSATB1 Promotes Colorectal Cancer Liver Metastasis through Facilitating FKBP8 Degradation via RNF25-Mediated Ubiquitination
83. o8G-modified circKIAA1797 promotes lung cancer development by inhibiting cuproptosis10.1186/s13046-025-03365-z ↗
84. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 201210.1002/ijc.29210 ↗
85. Epigenetic regulation of tumor immunity10.1172/JCI178540 ↗
86. Human memory CD8 T cell effector potential is epigenetically preserved during in vivo homeostasis10.1084/jem.20161760 ↗
87. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis10.1016/j.immuni.2016.07.011 ↗
88. Epigenetic remodelling under hypoxia10.1016/j.semcancer.2023.10.005 ↗
89. Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy10.1038/s41467-022-31764-9 ↗
90. Deciphering the role of histone modifications in memory and exhausted CD8 T cells10.1038/s41598-025-99804-0 ↗
91. Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells10.1126/sciimmunol.abj9123 ↗
92. Chromatin repression by PRC2 results in reduced gene expression driving key features of CD8 T cell exhaustion10.1093/jimmun/vkaf188 ↗
93. Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate10.1126/science.aaw1026 ↗
94. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation10.1038/s41586-020-2682-1 ↗
95. Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function10.1126/science.abj5104 ↗
96. Differentiation of effector CD4 T cell populations10.1146/annurev-immunol-030409-101212 ↗
97. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells10.1016/j.immuni.2013.09.012 ↗
98. An epigenetic silencing pathway controlling T helper 2 cell lineage commitment10.1038/nature11173 ↗
99. The Histone Methyltransferase SETDB1 Controls T Helper Cell Lineage Integrity by Repressing Endogenous Retroviruses10.1016/j.immuni.2019.01.003 ↗
100. Epigenetic initiation of the T(H)17 differentiation program is promoted by Cxxc finger protein 110.1126/sciadv.aax1608 ↗